Abstract
Current treatment of severe asthma is highly individualised. A prerequisite is the recognition of a clinically relevant phenotype.
In the case of failure of basic pharmacotherapy, phenotype-targeted biologic agents are indicated to significantly improve symptom scores, reduce the number of exacerbations, hospitalizations for asthma, or even allow the reduction or complete elimination of the need for total corticosteroids after several years. A number of new biologics are now available for severe allergic and non-allergic eosinophilic asthma.
However, this article discusses another very promising biologic with broad potential for action, not only in T2-high type asthma. It is tezepelumab, a humanized monoclonal antibody that binds to TSLP and blocks interaction with the receptor for TSLP.
Key studies and thus possible future indications in our severe asthma patients are also included.